Table 3.
Associations of ferritin levels in SVR patients at 24 weeks posttherapy.
| 24-week post-therapy factors | Univariate analyses | Multivariate analyses | ||
|---|---|---|---|---|
| 95% CI of OR (OR) | p values | 95% CI of OR (OR) | p values | |
| Male, yes | − 47.83 ~ 132.4 (42.29) | 0.357 | ||
| Age, (years) | − 1.49 ~ 5.71 (2.1) | 0.251 | ||
| BMI (kg/m2) | − 16.7 ~ 7.286 (− 4.7) | 0.44 | ||
| ALT (U/L) | 6.19 ~ 11.91 (9.052) | < 0.001 | 3.007 ~ 8.107 (5.557) | < 0.001 |
| eGFR (mL/min/1.73 m2) | − 4.526 ~ − 1.821 (− 3.17) | < 0.001 | − 3.9 ~ − 1.61 (− 2.76) | < 0.001 |
| TG (mg/dL) | 0.331 ~ 1.228 (0.779) | 0.001 | 0.146 ~ 0.909 (0.527) | 0.017 |
| TC (mg/dL) | 0.956 ~ 3.423 (2.189) | 0.001 | 0.211 ~ 2.346 (1.278) | 0.019 |
| HOMA-IR | − 0.689 ~ 29.63 (14.47) | 0.061 | − 5.03 ~ 20.09 (7.53) | 0.239 |
| Uric acid (mg/dL) | 33.59 ~ 91.36 (62.474) | < 0.001 | − 7.11 ~ 40.52 (16.70) | 0.169 |
| Fe/TIBC (%) | 1811 ~ 2338 (2075) | < 0.001 | 1521 ~ 2030 (1776) | < 0.001 |
| Hb (g/dL) | − 34.76 ~ 18.93 (− 7.91) | 0.563 | ||
| NLR | − 34.1 ~ 66.98 (16.45) | 0.523 | ||
| Platelet (103/μL) | − 2.06 ~ − 0.591 (− 1.29) | 0.001 | − 1.12 ~ 0.661 (− 0.234) | 0.608 |
| Steatosis, yes | − 177.8 ~ 86.3 (− 45) | 0.495 | ||
| Liver cirrhosis, yes | − 77.0 ~ 256.8 (89.92) | 0.29 | ||
| Fibrosis-4 index | − 2.56 ~ 42.1 (19.755) | 0.083 | − 4.36 ~ 47.8 (21.72) | 0.102 |
|
IFNL3-rs12979860 CC genotype, yes |
− 189.3 ~ 80.9 (− 54.2) | 0.431 | ||
| Therapy (interferon = 1, DAA = 2) | − 352 ~ − 170 (− 261) | < 0.001 | − 331 ~ − 161 (− 246) | < 0.001 |
OR odds ratio, BMI body mass index, ALT alanine transaminase, eGFR estimated glomerular filtration rate, TG triglycerides, TC total cholesterol, HOMA-IR homeostatic model assessment for insulin resistance, Fe/TIBC serum Iron/total iron binding capacity, Hb hemoglobin, NLR neutrophil lymphocyte ratio, FIB-4 fibrosis-4, IFNL3 interferon-λ3, DAA direct-acting antivirals.